P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY

• J.-Z. Hou,
• N. G. Daver,
• D. A. Stevens,
• T. Yamauchi,
• Y. Moshe,
• C. Y. Fong,
• A. Marzocchetti,
• R. Adamec,
• M. Patel,
• S. Lambert,
• K. Y. Wu,
• C. Röllig

Affiliations

J.-Z. Hou

1 UPMC Hillman Cancer Center, Pittsburgh, PA

N. G. Daver

2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

D. A. Stevens

3 Norton Cancer Institute, Louisville, KY, United States of America

T. Yamauchi

4 University of Fukui Hospital, Fukui, Japan

Y. Moshe

5 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

C. Y. Fong

6 Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia

A. Marzocchetti

7 AbbVie S.r.l., Rome, Italy

R. Adamec

8 AbbVie Inc., North Chicago, IL

M. Patel

8 AbbVie Inc., North Chicago, IL

S. Lambert

9 AbbVie Inc., South San Francisco, CA, United States of America

K. Y. Wu

8 AbbVie Inc., North Chicago, IL

C. Röllig

10 Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany